Similar articles

• Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

  Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
• Optimal dosage of ribavirin.

  Mangia A, Andriulli A. Mangia A, et al. Hepatology. 2010 Sep;52(3):1174. doi: 10.1002/hep.23742. Hepatology. 2010. PMID: 20812365 No abstract available.
• Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.

  Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Moreno C, et al. J Hepatol. 2010 Jan;52(1):25-31. doi: 10.1016/j.jhep.2009.10.003. Epub 2009 Oct 23. J Hepatol. 2010. PMID: 19931204
• Peginterferon and ribavirin for chronic hepatitis C.

  Hoofnagle JH, Seeff LB. Hoofnagle JH, et al. N Engl J Med. 2006 Dec 7;355(23):2444-51. doi: 10.1056/NEJMct061675. N Engl J Med. 2006. PMID: 17151366 Review. No abstract available.
• Optimal therapy in genotype 1 patients.

  Farnik H, Mihm U, Zeuzem S. Farnik H, et al. Liver Int. 2009 Jan;29 Suppl 1:23-30. doi: 10.1111/j.1478-3231.2008.01969.x. Liver Int. 2009. PMID: 19207963 Review.